Healthpeak Properties, Inc. (DOC)
(Delayed Data from NYSE)
$18.80 USD
+0.46 (2.51%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.82 +0.02 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Healthpeak (DOC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$20.92 | $26.00 | $18.00 | 14.07% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Healthpeak comes to $20.92. The forecasts range from a low of $18.00 to a high of $26.00. The average price target represents an increase of 14.07% from the last closing price of $18.34.
Analyst Price Targets (12)
Broker Rating
Healthpeak currently has an average brokerage recommendation (ABR) of 2.13 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 2.54 a month ago based on 13 recommendations.
Of the 15 recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 40% and 6.67% of all recommendations. A month ago, Strong Buy made up 23.08%, while Buy represented 7.69%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 5 | 3 | 6 | 6 |
Buy | 1 | 1 | 1 | 0 | 0 |
Hold | 8 | 8 | 8 | 7 | 6 |
Sell | 0 | 0 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 1 |
ABR | 2.13 | 2.21 | 2.54 | 2.21 | 2.36 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/22/2024 | Mizuho SecuritiesUSA | Vikram Malhotra | Not Available | Strong Buy |
3/6/2024 | KeyBanc Capital Markets | Austin Wurschmidt | Hold | Hold |
3/4/2024 | Scotiabank | Nicholas Yulico | Strong Buy | Strong Buy |
2/12/2024 | Exane BNP Paribas | Nathan D Crossett | Strong Sell | Hold |
11/3/2023 | Not Identified | Not Identified | Hold | Hold |
11/1/2023 | Wedbush Securities | Richard Anderson | Hold | Hold |
10/2/2023 | Evercore Partners | Stephen Sakwa | Strong Buy | Strong Buy |
8/15/2023 | Robert W. Baird & Co. | Wesley Golladay | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.13 |
ABR (Last week) | 2.21 |
# of Recs in ABR | 15 |
Average Target Price | $20.92 |
LT Growth Rate | 5.70% |
Industry | REIT and Equity Trust - Other |
Industry Rank by ABR | 156 of 252 |
Current Quarter EPS Est: | 0.44 |